ArticleRheumatology (Oxford, England)2026
Amyloidosis secondary to familial Mediterranean fever: machine learning-based prediction models.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Amyloidosis secondary to familial Mediterranean fever: machine learning-based prediction models.Rheumatology (Oxford, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesFMF is a monogenic autoinflammatory disease caused by MEFV mutations, with amyloidosis as its most severe complication. This study aimed to compare logistic regression, random forest, and gradient-boosting models to predict amyloidosis in FMF patients.
methodsPatients with FMF diagnosed between 1990 and 2022 at Cerrahpaşa Faculty of Medicine were retrospectively screened. Eligible patients with available clinical records were included. Clinical, genetic, and laboratory variables were extracted. Univariate analyses and pooled multivariate logistic regression were conducted. Logistic regression, random forest, and gradient-boosting machine-learning models were developed. Models were optimized by hyperparameter tuning and evaluated on a held-out test set.
resultsOf the 615 FMF patients included, 58 (9.4%) had amyloidosis. Patients with amyloidosis had earlier symptom onset, longer diagnostic delay and disease duration, were more often male, and more frequently carried M694V homozygosity. Comorbidities, parental consanguinity, frequent infections, erysipelas-like erythema, myalgia, arthritis, and higher median CRP levels were more prevalent in the amyloidosis group. In multivariate analysis, disease duration, M694V homozygosity, comorbidity, parental consanguinity, frequent infections, and erysipelas-like erythema were independently associated with amyloidosis. Random forest achieved the best performance on the test set (area under the receiver operating characteristic = 0.784), followed by logistic regression (0.766) and gradient boosting (0.749). SHAP analysis identified M694V homozygosity, myalgia, erysipelas-like erythema, disease duration, and arthritis as the strongest contributors to amyloidosis prediction.
conclusionAmyloidosis, the most severe FMF complication, is driven by key clinical and genetic factors, with ensemble machine-learning models outperforming conventional regression for early risk prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.